Analyst firms · BofA Securities · HAE
BofA Securities HAE price target and rating history
Haemonetics Corporation (HAE) · Health Care
BofA Securities rates Haemonetics Corporation (HAE) Buy with a $80 price target, as of its latest action on May 22, 2026. It has published 3 rating actions on HAE since September 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a HAE price target in the last 12 months, the median target is $106. BofA Securities's $80 is 25% below that.
- Current rating
- Buy
- Price target
- $80
- Median target, all firms
- $106
- Actions on HAE
- 3
BofA Securities price target on HAE
Every BofA Securities rating on HAE
- May 22, 2026
- Feb 7, 2025
- Sep 11, 2024
How other firms rate HAE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Buy | $150 | Nov 13, 2026 |
| Citigroup | Buy | $123 | Sep 17, 2026 |
| BofA Securities | Buy | $80 | May 22, 2026 |
| Barrington Research | Outperform | $89 | May 12, 2026 |
| Needham | Hold | Dec 15, 2025 |
Questions about BofA Securities and HAE
- What is BofA Securities's price target for HAE?
- BofA Securities's latest stated price target for Haemonetics Corporation (HAE) is $80, from its action on May 22, 2026.
- What is BofA Securities's rating on HAE?
- BofA Securities rates HAE Buy, a bullish rating, as of May 22, 2026.
- When did BofA Securities last change its view on HAE?
- On May 22, 2026, BofA Securities upgrades to Buy from Neutral, price target $80.
- How does BofA Securities's HAE target compare with other analysts?
- Across 4 firms with a HAE price target in the last 12 months, the median target is $106. BofA Securities's $80 is 25% below that.
More HAE rating histories
All BofA Securities ratingsHAE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.